Stockscreener 앱 받기
78.37
0.93%
0.72
Ani Pharmaceuticals Inc 주식(ANIP)의 최신 뉴스
ANI Pharmaceuticals Inc (ANIP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BlackRock (ANIP) discloses 2.9M-share, 12.8% stake in ANI Pharmaceuticals - Stock Titan
ANI Pharmaceuticals Inc (ANIP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ANI Pharmaceuticals Inc (ANIP) Cash Flow - TradingKey
TradingKey - TradingKey
ANI Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ANIP - TradingView
ANI Pharmaceuticals, Inc. (ANIP) Stock Forecasts - Yahoo! Finance Canada
Is ANI Pharmaceuticals (ANIP) A Bargain Following Its Positive SYNCHRONICITY Trial Results? - Yahoo Finance
ANI Pharmaceuticals Inc (ANIP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ANI Pharmaceuticals, Inc. (ANIP) Stock Price, News, Quote & History - Yahoo! Finance Canada
ANIP|ANI Pharmaceuticals Inc|Price:77.650|Chg%:-0.880 - TradingKey
ANIP|ANI Pharmaceuticals Inc|Price:78.370|Chg%:+0.720 - TradingKey
ANI Pharmaceuticals Inc (ANIP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ANI Pharmaceuticals Inc (ANIP) Valuation: PE, PB & Fair Value Analysis - TradingKey
ANI Pharmaceuticals Inc (ANIP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ANI Pharmaceuticals to report Q2 2026 earnings on August 7 with webcast discussion. - Pluang
ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET - The Manila Times
Three ANI Pharmaceuticals executives will host Aug. 7 results call - Stock Titan
ANI Pharmaceuticals Inc (ANIP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ANIP5868601 Bond Profile — Key Metrics - TradingView
ANI Pharmaceuticals (ANIP) GC has 2,466 shares withheld for taxes on RSU vesting - Stock Titan
US Generic Drug Stocks With Domestic Manufacturing in Focus - Sahm
ANI Pharmaceuticals (ANIP) On Strong ILUVIEN Trial Data Is The Stock A Bargain - Sahm
How Positive SYNCHRONICITY Trial Data for ILUVIEN at ANI Pharmaceuticals (ANIP) Has Changed Its Investment Story - Sahm
Is ANI Pharmaceuticals Inc (ANIP) a Bargain After 3.3% Drop? GF Value Says Undervalued - GuruFocus
ANI PHARMACEUTICALS INC : CANACCORD GENUITY INITIATES COVERAGE WITH HOLD RATING; TARGET PRICE $91 - Bitget
ANI Pharmaceuticals plans appeal after trial court ruling - Investing.com UK
Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target? - qz.com
ANIP's Cortrophin Gel Surge Powers 2026 Growth Outlook - qz.com
ANI Pharmaceuticals' 2026 Catalysts Include Gout Push and New Generics - qz.com
ANI Pharmaceuticals plans appeal after trial court ruling By Investing.com - Investing.com South Africa
Ani Pharmaceuticals Announces Intent To Appeal Rulings In CG Oncology Matter - TradingView
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter - The Manila Times
ANI Pharmaceuticals to Appeal Delaware Ruling Denying Post-Trial Motions in CG Oncology Asset Dispute - Quiver Quantitative
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run - AOL.com
symbol__ Stock Quote Price and Forecast - CNN
Frontier tech research, news & data - MLQ.ai
Insider Sell: Meredith Cook Sells 500 Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus
ANI Pharmaceuticals shares rise on positive eye implant trial amid insider stock sales - Pluang
ANI Pharmaceuticals (ANIP) counsel sells 500 shares under 10b5-1 plan - Stock Titan
ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant - Proactive financial news
ANI Pharmaceuticals reports positive uveitis trial results - grafa.com
ANI Pharmaceuticals reports positive phase 4 trial results By Investing.com - Investing.com South Africa
ANI Pharmaceuticals reports positive phase 4 trial results - Investing.com
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis - The Manila Times
ANI Pharmaceuticals Announces Positive Six-Month Topline - GlobeNewswire
ANI Pharmaceuticals reports positive 6-month da... - Pluang
Enterprise value to EBIT forward of ANI Pharmaceuticals, Inc. – BX:BSFA - TradingView
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run - The Motley Fool
ANI Pharmaceuticals (ANIP) Recalls HydrOXYzine Solution, Is The Pullback A Valuation Opportunity? - Sahm
ANI Pharmaceuticals Inc (ANIP) Institutional Confidence - TradingKey
ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge - The Globe and Mail
Enterprise value to revenue forward of ANI Pharmaceuticals, Inc. – NASDAQ:ANIP - TradingView
0.30%
2.01%
자본화:
|
볼륨(24시간):